Pyrimethamine decreases levels of SOD1 in leukocytes and cerebrospinal fluid of ALS patients: A phase i pilot study

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Volumn 14, Issue 3, 2013, Pages 199-204

  Lange, Dale J ^a   Andersen, Peter M ^b   Remanan, Rahul ^a   Marklund, Stefan ^c   Benjamin, Daniel ^d  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

^d Cenoxsys Corporation Inc   (United States)

Author keywords

ALS; Clinical trials; Pyrimethamine; SOD1; Therapy

Indexed keywords

ACTIN; COPPER ZINC SUPEROXIDE DISMUTASE; CORTICOSTEROID; PYRIMETHAMINE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BLOOD SAMPLING; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG INDUCED HEADACHE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; LEUKOCYTE; MALAISE; MALE; MUTATION; NAUSEA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; RASH; SAMPLING; SEIZURE; SPECTROPHOTOMETRY; TINNITUS; WESTERN BLOTTING;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL MARKERS; FEMALE; HUMANS; LEUKOCYTES; MALE; MIDDLE AGED; PILOT PROJECTS; PYRIMETHAMINE; SUPEROXIDE DISMUTASE;

EID: 84875749166     PISSN: 21678421     EISSN: 21679223     Source Type: Journal    
DOI: 10.3109/17482968.2012.724074     Document Type: Article

References (25)

1. Andersen PM, Al-Chalabi A. Clinical genetics of amyo-trophic lateral sclerosis: what do we really know? Nat Rev Neurol. 2011; 7: 603-15.
2. Weber M, Neuwirth C, Thierbach J, Schweikert K, Czaplinski A, Petersen J, et al. ALS patients with SOD1 mutations in Switzerland show very diverse phenotypes and extremely long survival. J Neurol Neurosurg Psychiatry. 2012; 83: 351-3.
3. Andersen PM, Nilsson P, Keranen ML, Forsgren L, Hagglund J, Karlsborg M, et al. Phenotypic heterogeneity in motor neuron disease patients with Cu/Zn superoxide dis-mutase mutations in Scandinavia. Brain. 1997; 120: 1723-37.
4. Andersen PM, Sims KB, Xin WW, Kiely R, O'Neill G, Ravits J, et al. Sixteen novel mutations in the Cu/Zn super-oxide dismutase gene in amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003; 4: 62-73.
5. Pasinelli P, Brown RH. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci. 2006; 7: 710-23.
6. Israelson A, Arbel N, Da Cruz S, Ilieva H, Yamanaka K, Shoshan-Barmatz V, et al. Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS. Neuron. 2010; 67: 575-87.
7. Allen MJ, Lacroix JJ, Ramachandran S, Capone R, Whitlock JL, Ghadge GD, et al. Mutant SOD1 forms ion channel: implications for ALS pathophysiology. Neurobiol Dis. 2012; 45: 831-8.
8. Alexander GM, Erwin KL, Byers N, Deitch JS, Augelli BJ, Blankenhorn EP, et al. Effect of transgene copy number on survival in the G93A-SOD1 transgenic mouse model of ALS. Brain Res Mol Brain Res. 2004; 130: 7-15.
9. Jonsson P A, Graffmo KS, Andersen PM, Brannstrom T, Lindberg M, Oliveberg M, et al. Disulfide-reduced superox-ide dismutase-1 in CNS of transgenic amyotrophic lateral sclerosis models. Brain. 2006; 129: 451-64.
10. Scott SED, San Francisco, California 94132, US, Benjamin, Daniel (56 Prodelin Way, Englishtown, New Jersey 07726, US), inventor Alsgen, Inc. (11 Deer Park Drive, Suite 123, Monmouth Junction, NJ 08852, US), assignee. Treatment of Amyotrophic Lateral Sclerosis with Pyrimethamine and Analogues, 2010.
11. Benjamin DE, Rex BT, Kelly N, Scott S. Inhibition of SOD1 protein expression in the cell by pyrimethamine, an orally available small molecule. International symposium on ALS/MND. 2007.
12. Benjamin DE, Henrie RN, Errico MA, Rex BT, Bracken JD, Scott S. Heterocyclic compound superoxide dismutase inhibitors for modulation of neurodegenerative diseases. US Pat Appl Publ. [Patent]. 2007.
13. Klinker H, Langmann P, Richter E. Plasma pyrimethamine concentrations during long-term treatment for cerebral tox-oplasmosis in patients with AIDS. Antimicrob Agents Chem-other. 1996; 40: 1623-7.
14. McLeod R, Mack D, Foss R, Boyer K, Withers S, Levin S, et al. Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxo-plasmosis. Toxoplasmosis Study Group. Antimicrob Agents Chemother. 1992; 36: 1040-8.
15. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial ' Clinical limits of amyotrophic lateral sclerosis ' workshop contributors. J Neurol Sci. 1994; 124(Suppl): 96-107.
16. Haverkamp LJ, Appel V, Appel SH. Natural history of amyo-trophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain. 1995; 118: 707-19.
17. Zetterstrom P, Andersen PM, Brannstrom T, Marklund SL. Misfolded superoxide dismutase-1 in CSF from amyotrophic lateral sclerosis patients. J Neurochem. 2011; 117: 91-9.
18. Marklund S. Spectrophotometric study of spontaneous dis-proportionation of superoxide anion radical and sensitive direct assay for superoxide dismutase. J Biol Chem. 1976; 251: 7504-7.
19. Marklund SL, Andersen PM, Forsgren L, Nilsson P, Ohlsson PI, Wikander G, et al. Normal binding and reactivity of copper in mutant superoxide dismutase isolated from amyotrophic lateral sclerosis patients. J Neurochem. 1997; 69: 675-81.
20. Jacobsson J, Jonsson PA, Andersen PM, Forsgren L, Marklund SL. Superoxide dismutase in CSF from amyo-trophic lateral sclerosis patients with and without Cu/Zn superoxide dismutase mutations. Brain. 2001; 124: 1461-6.
21. Maegawa GH, Tropak M, Buttner J, Stockley T, Kok F, Clarke JT, et al. Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosido-sis. J Biol Chem. 2007; 282: 9150-61.
22. Alloueche A, Bailey W, Barton S, Bwika J, Chimpeni P, Falade CO, et al. Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomized controlled trial. Lancet. 2004; 363: 1843-8.
23. Wright PD, Huang M, Weiss A, Matthews J, Wightman N, Glicksman M, et al. Screening for inhibitors of the SOD1 gene promoter: pyrimethamine does not reduce SOD1 levels in cell and animal models. Neurosci Lett. 2010; 482: 188-92.
24. Forsberg K, Jonsson PA, Andersen PM, Bergemalm D, Graffmo KS, Hultdin M, et al. Novel antibodies reveal inclusions containing non-native SOD1 in sporadic ALS patients. PLoS One. 2010; 5: 11552.
25. Bosco DA, Morfini G, Karabacak NM, Song Y, Gros-Louis F, Pasinelli P, et al. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci. 2010; 13: 1396-403.